Table 1 Clinical characteristics of patients with type 2 diabetes mellitus (T2DM) treated with SGLT2i
|  | Patient enrollment (n = 8992) |
|---|---|
Clinical characteristics | |
 Diabetes duration (year) | 8.6 ± 3.4 |
 Age (year) | 58.8 ± 11.3 |
 Female | 3864 (43) |
 Ischemic heart etiology | 633 (7) |
 Hypertension | 6032 (67) |
 Dyslipidemia | 7026 (78) |
 Cerebral vascular accidents | 361 (4) |
 Congestive heart failure | 291 (3) |
 Peripheral artery disease | 74 (1) |
 Gout | 924 (10) |
 Malignancy | 734 (8) |
Baseline body weight (BW) and BW change | |
 Baseline body weight (kg) | 74.0 ± 15.1 |
 Baseline BMI (kg/m2) | 27.9 ± 4.7 |
 Body weight change (kg) | − 1.24 ± 2.83 |
 Body weight change (%) | − 1.65 ± 3.84 |
Baseline laboratory data | |
 HbA1c (%) | 8.9 ± 1.6 |
 eGFR (ml/min/1.73 m2) | 93.3 ± 22.0 |
 Triglycerides (mg/dL) | 180.3 ± 204.7 |
 LDL (mg/dL) | 92.5 ± 29.7 |
 HDL (mg/dL) | 43.9 ± 11.2 |
 Uric acid (mg/dL) | 5.7 ± 1.4 |
 Urine ACR (mg/g) | 236.9 ± 787.8 |
Baseline medications | |
 Anti-platelet agent | 2809 (31) |
 Statin | 5703 (63) |
 ACEI or ARB | 5371 (60) |
 Use of diuretics | 787 (9) |
Anti-diabetic agent | Â |
 SU | 6203 (69) |
 Metformin | 8229 (92) |
 Glinide | 297 (3) |
 DPP4i | 4564 (51) |
 Glitazone | 2340 (26) |
 Acarbose | 1955 (22) |
 Insulin | 1736 (19) |
 GLP1 agonist | 84 (1) |